Ivabradine Patent Expiration

Ivabradine is Used for treating heart failure in humans. It was first introduced by Amgen Inc in its drug Corlanor on Apr 22, 2019.


Ivabradine Patents

Given below is the list of patents protecting Ivabradine, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Corlanor US7867996 γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it Dec 12, 2026 Amgen Inc
Corlanor US7361649 β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it Feb 22, 2026 Amgen Inc
Corlanor US7361650 γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it Feb 22, 2026 Amgen Inc
Corlanor US7879842 Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it Feb 22, 2026 Amgen Inc



Ivabradine's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List